About This Project

Arteriovenous Fistulas (AVF), the process of joining a vein to an artery, is the gold standard for both vascular access (VA) and haemodialysis (HD) in end-stage renal disease (ESRD) patients, however, the procedure is fraught with post-surgical complications, leading to a 65% rate of usability 3-months after the surgery. VasQ is an external support device which wraps the vein to provide structural support, and braces it against the artery to improve flow properties, presenting a drastic improvement over both conventional AVF procedures and the competing alternative technologies. By providing structural support to the vein in the AVF, and bracing the site where the artery and vein (the anastomosis) are joined at an optimal interface angle, VasQ prevents complications relating to a vein being subjected to arterial conditions (stenosis, aneurysm, rupture), and the flow-pattern problems (thrombosis, shear force complications), respectively. The implementation of VasQ does not alter the AVF procedure, ensuring that the surgeons do not need to learn a new work process. Overall, VasQ provides repeatable, superior results to both unsupported AVFs and alternative procedures, and improves the long-term usability of AVFs; this reduces the cost to patients and healthcare providers. Through these superior results, and by not altering a trusted procedure, VasQ provides psychological security to the surgeon and the patient that their combined effort will not be wasted. Overall, VasQ improves the maturation success rate to 87% at 3 months and proven a 3x improvement in flow rates of the AVF over the accepted minimum standard for maturation, and a 60% improvement in venous diameter over the accepted minimum standard within 3 months


PHC-12 - Clinical research for the validation of biomarkers and/or diagnostic medical devices






Laminate Medical